Application Note: WB: 0.3-1μg/ml. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
Calculated MW: 33
Positive Control: The peptide used to generate this antibody is available for purchase (GTX89488-PEP).
Specificity/Sensitivity: This antibody is expected to recognise isoforms 1to 4 (NP_000107.1; NP_851828.1; NP_851829.1; NP_851830.1, respectively).
Form: Liquid
Buffer (with preservative): TBS, 0.5% BSA, 0.02% Sodium azide.
Concentration: 0.50 mg/ml (Please refer to the vial label for the specific concentration.)
Background: This gene encodes a protein that is expressed at high levels in cardiac and skeletal muscle. Mutations in this gene have been associated with a number of clinical disorders including Barth syndrome, dilated cardiomyopathy (DCM), hypertrophic DCM, endocardial fibroelastosis, and left ventricular noncompaction (LVNC). Multiple transcript variants encoding different isoforms have been described. A long form and a short form of each of these isoforms is produced; the short form lacks a hydrophobic leader sequence and may exist as a cytoplasmic protein rather than being membrane-bound. Other alternatively spliced transcripts have been described but the full-length nature of all these transcripts is not known. [provided by RefSeq, Jul 2008]
Uniprot ID: Q16635
Antigen Species: Human
Immunogen: Peptide with sequence C-HLKTQAEQLHNH, from the C Terminus of the protein sequence according to NP_000107.1; NP_851828.1; NP_851829.1; NP_851830.1.
Purification: Purified by ammonium sulphate precipitation followed by antigen affinity chromatography
Conjugation: Unconjugated
Full Name: tafazzin
English
Deutsch
